Dermatomyositis

  • Constantin E. Orfanos
  • Claus Garbe

Zusammenfassung

Die Dermatomyositis (DM) ist eine chronische, in Schüben verlaufende Systemerkrankung des Haut- und Muskelgewebes, vermurlich, auf autoimmunologischer Grundlage; sie ist im Vergleich zum LE oder der Sklerodermie, ein seltenes Krankheitsbild. Zu unterscheiden ist eine adulte Form im 5.–7. Dezenium und eine juvenile Variante, die sich meist bereits vor dem 10. Lebensjahr manifestiert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abdel Naser BM, Chun SC, Gollnick H, Orfanos CE (1993) Amyopathic dermatomyositis (dermatomyositis sine myositis) in a male patient and possible induction by UV light. Eur J Dermatol 3: 367–370Google Scholar
  2. Basset-Sequin N, Roujeau J-C, Gherardi R (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Arch Dermatol 126: 633–637CrossRefGoogle Scholar
  3. Bernard P, Bonnetblanc JM (1993) Dermatomyositis and malignancy. J Invest Dermatol 100: 128–132CrossRefGoogle Scholar
  4. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56: 255–286PubMedCrossRefGoogle Scholar
  5. Callen J (1985) Dermatomyositis — an update 1985. Sem Dermatol 4: 114–125Google Scholar
  6. Cox PH, Lawrence C, Langtry JAA, Ive A (1990) Dermatomyositis. Arch Dermatol 126: 61–65PubMedCrossRefGoogle Scholar
  7. Euwer RL, Sontheimer RD (1991) Amyopathic dermatomyositis (dermatomyositis sine myositis). J Am Acad Dermatol 24: 959–966PubMedCrossRefGoogle Scholar
  8. Henriksson KG, Sandstedt P (1982) Polymyositis treatment and prognosis: a study of 107 patients. Acta Neurol Scand 65: 280–300PubMedCrossRefGoogle Scholar
  9. Lakhanpal S, Bunch TW,Ilstrup DM, Melton LJ (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61: 645–653Google Scholar
  10. Love LA, Leff RL, Fraser DD et al. (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70: 360–374PubMedCrossRefGoogle Scholar
  11. Manchul LA, Jin A, Pritchard KI et al. (1985) The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. Arch Intern Med 145: 1835–1839PubMedCrossRefGoogle Scholar
  12. Rockerbie NR, Woo TY, Callen JP, Giustina T (1989) Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 20: 629–632PubMedCrossRefGoogle Scholar
  13. Sigurgeirsson B (1992) Skin disease and malignancy: an epidemiological study. Acta Derm Venereol [Suppl] 178: 1–110Google Scholar
  14. Sigurgeirsson V, Lindelöf B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 326: 363–367PubMedCrossRefGoogle Scholar
  15. Stonecipher MR, Jorizzo JL, White WL et al. (1993) Cutaneous changes of dermatomyositis in patients with normal muscle enzymes. Dermatomyositis sine myositis? J Am Acad Dermatol 28: 951–956PubMedCrossRefGoogle Scholar
  16. Trautmann Ch, Abdel Naser BM, Soehnchen R et al. (1995) Prämyopathische vs. amyopathische Dermatomyositis. Hautarzt 46: 47–52PubMedCrossRefGoogle Scholar
  17. Bodemer C, Teillac D, Le Bourgeois M et al. (1990) Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol 123: 545–546PubMedCrossRefGoogle Scholar
  18. Bombardieri S, Hughes GRV, Neri et al. (1989) Cyclophosphamid in severe polymyositis. Lancet I: 1138–1139Google Scholar
  19. Boyd AS, Neldner KH (1994) Therapeutic options in dermatomyositis/polymyositis. Intern J Dermatol 33: 240–250CrossRefGoogle Scholar
  20. Bunch TW (1981) Prednisone and azathioprine for polymyositis: longterm-follow-up. Arthritis Rheum 24: 45–48PubMedCrossRefGoogle Scholar
  21. Casato M, Bonomo L, Caccavo D, Giorgi (1989) Clinical effects of cyclosporin in dermatomyositis. Clin Exp Dermatol 15: 121–123Google Scholar
  22. Cherin P, Herson S, Wechsler B (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91: 162–168PubMedCrossRefGoogle Scholar
  23. Dau PC (1981) Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol 38: 544–552PubMedCrossRefGoogle Scholar
  24. Derancourt C, Humbert P, Agache P (1992) Immun-globulines polyvalentes intraveineuses: utilisation en dermatologie. Ann Dermatol Vénéréo1119: 487–488Google Scholar
  25. Herson S, Lok C, Ronjeau JC et al. (1989) Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 patients of plasma exchange. Ann Med Intern Paris 1040: 453–455Google Scholar
  26. MacPherson A, Berth CC, Graham BRA (1989) Carcinoma-associated dermatomyositits responding to plasmapheresis. Clin Exp Dermatol 14: 304–305PubMedCrossRefGoogle Scholar
  27. Metzger AL, Bohan A, Goldberg LS et al. (1974) Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 81: 182–189PubMedGoogle Scholar
  28. Morgan SH, Bernstein RM, Coppen J et al. (1985) Total body irradiation and the course of polymyositis. Arthritis Rheum 28: 831–835PubMedCrossRefGoogle Scholar
  29. Lang BA, Laxer RM, Murphy G et al. (1991). Treatment of dermatomyositis with intravenous gamma-globulin. Am J Med 91: 169–172PubMedCrossRefGoogle Scholar
  30. Sinoway PA, Callen JP (1993) Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 36: 319–324PubMedCrossRefGoogle Scholar
  31. Susa Y, Ikeda S, Yamada H, Ogawa H (1993) Double filtration plasmapheresis for the treatment of dermatomyositis. Clinical trial of 3 cases. Eur J Dermatol 3: 438–441Google Scholar
  32. Targoff JN (1993) Humoral immunity in polymyositis/ dermatomyositis. J Invest Dermatol 100: 1165–123SCrossRefGoogle Scholar
  33. Woo TY, Callen JP, Voorhees JJ et al. (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10: 592–600PubMedCrossRefGoogle Scholar
  34. Anderson L, Liter FA (1981) Plasmapheresis via central catheter in dermatomyositis. A new method for selected pediatric patients. J Pediatr 98: 200–241Google Scholar
  35. Ansell BM (1991) Juvenile Dermatomyositis. Rheum Dis Clin North Am 17: 931–942PubMedGoogle Scholar
  36. Collet E, Dalac S, Maerens B et al. (1994) Juvenile Dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 130: 231–234PubMedCrossRefGoogle Scholar
  37. Heckmatt J, Hasson N, Saunders C et al. (1987) Cyclosporin in juvenile dermatomyositis. Lancet I: 1063–1066Google Scholar
  38. Hiketa T, Matsumo Y, Ohashi M, Sasaki R (1992) Juvenile dermatomyositis: A statistical study on 114 patients with dermatomyositis. J Dermatol 19: 470–476PubMedGoogle Scholar
  39. Lang BA, Laxer RM, Murphy G et al. (1991) Treatment of dermatomyositis with intravenous gamma-globulin. Amer J Med 91: 69–72CrossRefGoogle Scholar
  40. Norins AL (1989) Juvenile dermatomyositis. Med Clin North Am 73: 1193–1209PubMedGoogle Scholar
  41. Olson NY, Lindsley CB (1989) Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 16: 1545–1547PubMedGoogle Scholar
  42. Wang WJ, Lo WL, Wong CK (1988) Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminium hydroxide therapy. Arch Dermatol 124: 1721–1722PubMedCrossRefGoogle Scholar
  43. Bernstein RM, Morgan SH, Chapmann J et al. (1984) Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 289: 151–152CrossRefGoogle Scholar
  44. Love LA, Leff RL, Fraser DD et al. (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define homogenous patient groups. Medicine 70: 360–374PubMedCrossRefGoogle Scholar
  45. Mirande M (1991) Aminoacyl-tRNA synthetase family from prokaryotes and eukaryotes: structural domains and their implications. Prog Nucleic Acid Res Mol Biol 40: 95–142PubMedCrossRefGoogle Scholar
  46. Yoshida S, Akizuki M, Mimori M et al. (1983) The precipitating antibody to an acid nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 26: 604–611Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Constantin E. Orfanos
    • 1
  • Claus Garbe
    • 1
  1. 1.Universitäts-Hautklinik und PoliklinikKlinikum Benjamin Franklin der Freien Universität BerlinBerlinDeutschland

Personalised recommendations